Table 1.
Study population.
| Baseline (N = 2661) | FU1 (N = 2195) | FU2 (N = 1878) | |
|---|---|---|---|
| Gender, N (%) | |||
| Female | 2058 (77.9) | 1726 (79.3) | 1464 (78.5) |
| Male | 574 (21.7) | 444 (20.4) | 394 (21.1) |
| Divers | 9 (0.3) | 7 (0.3) | 6 (0.3) |
| Age [years], median (range) | 45.2 (18.0–83.8) | 45.5 (18.0–81.0) | 46.7 (18.1–83.8) |
| MS disease course, N (%) | |||
| RRMS | 1987 (74.7) | 1656 (75.4) | 1405 (74.8) |
| SPMS | 456 (17.1) | 368 (16.8) | 326 (17.4) |
| PPMS | 102 (3.8) | 78 (3.6) | 70 (3.7) |
| Undefined | 116 (4.4) | 93 (4.2) | 77 (4.1) |
| Disability level (PDDS), N (%) | |||
| Mild (0–1) | 1376 (51.7) | 1194 (54.6) | 979 (52.4) |
| Moderate (2–4) | 965 (36.3) | 735 (33.6) | 664 (35.6) |
| Severe (≥5) | 320 (12.0) | 256 (11.7) | 224 (12.0) |
| Coincident autoimmune diseases, N (%) | 572 (21.5) | 479 (21.8) | 396 (21.1) |
| DMD treatment, N (%) | 1921 (72.2) | 1603 (73.1) | 1392 (74.1) |
| IFNβ/GLAT | 571 (30.4 a) | 488 (31.1 b) | 418 (30.7 c) |
| CLAD/DMF/TER | 533 (28.4 a) | 451 (28.8 b) | 391 (28.8 c) |
| S1P RM | 333 (17.7 a) | 275 (17.5 b) | 248 (18.2 c) |
| anti-CD20 MAB | 287 (15.3 a) | 222 (14.2 b) | 187 (13.8 c) |
| Natalizumab | 125 (6.6 a) | 104 (6.6 b) | 91 (6.7 c) |
| Other | 31 (1.6 a) | 28 (1.8 b) | 25 (1.8 c) |
| Relapse within the year prior to X1, N (%) | 391 (14.7) | 315 (14.4) | 262 (14.0) |
| Relapse within 6 months prior to X1, N (%) | 213 (8.0) | 169 (7.7) | 139 (7.4) |
| Relapse within 3 months prior to X1, N (%) | 100 (3.8) | 77 (3.5) | 60 (3.2) |
| Time from last relapse (before X1) to X1 [years], median (range) | 3.1 (0.03–40.7) | 3.2 (0.03–40.7) | 3.2 (0.03–40.7) |
a—referring to 1880 patients with detailed data on the DMD used (baseline); anti-CD20 MAB—anti-CD 20 monoclonal antibody: ocrelizumab/ofatumumab/rituximab; b—referring to 1568 patients with detailed data on the DMD used (FU1); CLAD/DMF/TER—cladribine/dimethyl fumarate/teriflunomide; c—referring to 1360 patients with detailed data on the DMD used (FU2); DMD—disease-modifying drug; FU—follow-up; IFNβ/GLAT—interferon beta-1a/interferon beta-1b/peginterferon beta-1a/glatiramer acetate; MS—multiple sclerosis; N—number of patients; PDDS—patient-determined disease steps; PPMS—primary progressive MS; RRMS—relapsing–remitting MS; S1P RM—sphingosin-1-phosphate receptor modulator: fingolimod/ozanimod/siponimod; SARS-CoV-2—severe acute respiratory syndrome coronavirus 2; SPMS—secondary progressive MS; X1—first SARS-CoV-2 vaccination.